FunPep Company Limited (4881.T)
- Previous Close
101.00 - Open
101.00 - Bid 100.00 x --
- Ask 100.00 x --
- Day's Range
99.00 - 102.00 - 52 Week Range
85.00 - 240.00 - Volume
222,700 - Avg. Volume
1,069,925 - Market Cap (intraday)
3.342B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-31.98 - Earnings Date May 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.
www.funpep.co.jpRecent News: 4881.T
View MorePerformance Overview: 4881.T
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4881.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4881.T
View MoreValuation Measures
Market Cap
3.28B
Enterprise Value
932.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
534.24
Price/Book (mrq)
1.29
Enterprise Value/Revenue
152.15
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.11%
Return on Equity (ttm)
-36.68%
Revenue (ttm)
6M
Net Income Avi to Common (ttm)
-889M
Diluted EPS (ttm)
-31.98
Balance Sheet and Cash Flow
Total Cash (mrq)
2.35B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-219.12M